Breaking News

Evusheld protects the vulnerable from Covid. Why are so few using it?; 5 burning questions about Amazon’s $3.9 billion acquisition of One Medical

 

Daily Recap

As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused

By Jason Mast

Ted S. Warren/AP

The drug was approved eight months ago as the best safeguard for immunocompromised patients. But the word does not seem to have spread far.

Read More

STAT+: 5 burning questions about Amazon's $3.9 billion acquisition of One Medical

By Mohana Ravindranath and Casey Ross and Bob Herman

Alex Hogan/STAT

STAT asked experts about the burning questions raised by Amazon's $3.9 billion acquisition of primary care company One Medical.

Read More

'There's no one long Covid': Experts struggle to make sense of the continuing mystery

By Elizabeth Cooney

Brandon Bell/Getty Images

A group of virologists gathered to ask and answer questions about what causes long Covid, how to predict who gets it, and how to treat it.

Read More

STAT+: Amazon has big ambitions in primary care. One Medical is just the latest piece of its plan

By Tara Bannow

Crossover Health

Amazon has been building its primary care prowess for years. The tech giant’s One Medical deal adds to an already expansive infrastructure. 

Read More

Acne bacteria, study suggests, thrive when skin oil turns infection-fighting cells into accomplices 

By Isabella Cueto

Adobe

The crunchy Cheeto-shaped bugs benefit because a component of skin oil turns fighting cells into indolent gluttons.

Read More

Opinion: New price transparency regulations for hospitals, insurers empower patients

By Seema Verma and Aneesh Chopra

David Goldman/AP

New health care price transparency regulations are lifting the veil on a sector that accounts for nearly 20% of the U.S. economy.

Read More

Friday, July 22, 2022

STAT

Facebook   Twitter   YouTube   Instagram

1 Exchange Pl, Suite 201, Boston, MA 02109
©2022, All Rights Reserved.
I no longer wish to receive STAT emails
Update Email Preferences | Contact Us | View In Browser

No comments